New Market Research Report: Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment And Market Forecasts To 2019

Recently published research from GlobalData, "Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019", is now available at Fast Market Research

by Bill Thompson

(WireNews+Co) - Boston, MA - 19 October 2012

GlobalData, the industry analysis specialist, has released its new report, "Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Supraventricular Tachycardia (SVT) Therapeutics market. The report identifies the key trends shaping and driving the global Supraventricular Tachycardia (SVT) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Supraventricular Tachycardia (SVT) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

View Full Report Details and Table of Contents (http://www.fastmr.com/prod/452651_supraventricular_tachycardia_svt_therapeutics.aspx) (http://www.fastmr.com/prod/452651_supraventricular_tachycardia_svt_therapeutics.aspx)

Scope

The report provides information on the key drivers and challenges of the Supraventricular Tachycardia (SVT) Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Supraventricular Tachycardia (SVT) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Supraventricular Tachycardia (SVT) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Supraventricular Tachycardia (SVT) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Supraventricular Tachycardia (SVT) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Supraventricular Tachycardia (SVT) Therapeutics market.
-

Companies Mentioned in this Report: Pfizer, Bristol-Myers Squibb, Cardiome Pharma, Daiichi Sankyo Inc., ARCA biopharma, Sanofi, Boehringer Ingelheim, Bayer HealthCare

Fast Market Research (http://www.fastmr.com) is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.